Nirmatrelvir/ritonavir for patients with SARS-CoV-2 infection and impaired kidney function during the Omicron surge
Jiayi Yan, Hong Cai, Jieying Wang, Mingli Zhu, Ping Li, Peiying Li, Bin Wu, Xiajing Che, Leyi Gu, Shan Mou
Frontiers in Pharmacology, doi:10.3389/fphar.2023.1147980
Background: Nirmatrelvir/ritonavir has demonstrated effectiveness in high-risk patients with coronavirus disease 2019 . However, investigations on the efficacy and safety of nirmatrelvir/ritonavir in patients with kidney dysfunction are limited. Methods: Data were collected from the patients admitted to a COVID-19 referral center in Shanghai, China. Patients were at least 18 years of age and had a baseline estimated glomerular filtration rate (eGFR) of <60 ml/min/1•73 m 2 . The primary endpoint was a composite of all-cause mortality, intensive care unit admission, or cardiovascular events. The secondary endpoint was viral shedding. Results: Among the 195 participants, 73 received nirmatrelvir/ritonavir. A lower risk of the primary endpoint was observed in nirmatrelvir/ritonavir recipients compared with non-recipients [adjusted HR 0.56 (95% CI: 0.32-0.96); p = 0.035]. Nirmatrelvir/ritonavir recipients experienced a shorter duration of viral shedding ; p < 0.001) and faster viral load clearance versus non-recipients. Among the nirmatrelvir/ritonavir users, earlier initiation of nirmatrelvir/ritonavir within 5 days since COVID-19 diagnosis was related with shorter viral shedding time ; p < 0.001) compared to late initiation. No patients reported serious adverse events during treatment.
Conclusion: Our findings support the early initiation of nirmatrelvir/ritonavir for high-risk patients with impaired kidney function. This could improve patient outcomes and shorten the viral shedding period.
Ethics statement The studies involving human participants were reviewed and approved by Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. The ethics committee waived the requirement of written informed consent for participation.
Author contributions JY, SM, and LG designed the study. JY, HC, and JW analyzed the data and revised the manuscript. JY and SM drafted and edited the final manuscript. All authors took part in collecting and verifying the
Conflict of interest The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher's note All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Supplementary material The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2023.1147980/ full#supplementary-material
References
Arbel, Wolff Sagy, Hoshen, Battat, Lavie et al., Nirmatrelvir use and severe covid-19 outcomes during the omicron surge, N. Engl. J. Med,
doi:10.1056/NEJMoa2204919Carlson, Nelveg-Kristensen, Freese Ballegaard, Feldt-Rasmussen, Hornum et al., Increased vulnerability to COVID-19 in chronic kidney disease, J. Intern Med,
doi:10.1111/joim.13239Christensen, Olsen, Long, Snehal, Davis et al., Signals of significantly increased vaccine breakthrough, decreased hospitalization rates, and less severe disease in patients with coronavirus disease 2019 caused by the omicron variant of severe acute respiratory syndrome coronavirus 2 in houston, Texas, Am. J. Pathol,
doi:10.1016/j.ajpath.2022.01.007Dejnirattisai, Huo, Zhou, Zahradnik, Supasa et al., None
Gnanenthiran, Borghi, Burger, Caramelli, Charchar et al., Renin-angiotensin system inhibitors in patients with COVID-19: A metaanalysis of randomized controlled trials led by the international society of hypertension, J. Am. Heart Assoc,
doi:10.1161/JAHA.122.026143Hammond, Leister-Tebbe, Gardner, Abreu, Bao et al., Risk factors for intensive care unit admission and in-hospital mortality among hospitalized adults identified through the US coronavirus disease 2019 (COVID-19)-Associated hospitalization surveillance network (COVID-NET), Nat. Rev. Microbiol,
doi:10.1093/cid/ciaa1012Levey, Stevens, Schmid, Zhang, Castro et al., None
Lingscheid, Kinzig, Kruger, Muller, Bolke et al., Pharmacokinetics of nirmatrelvir and ritonavir in COVID-19 patients with endstage renal disease on intermittent hemodialysis, Antimicrob. Agents Chemother
Lu, Zhang, Zhang, Ai, He et al., Geriatric risk and protective factors for serious COVID-19 outcomes among older adults in Shanghai Omicron wave, Emerg. Microbes Infect,
doi:10.1080/22221751.2022.2109517Mahase, Nahhas, Webster, Owen, The promising use of nanomolecular imprinted templates for improved SARS-CoV-2 detection, drug delivery and research,
doi:10.1126/science.abl4784Ozturk, Turgutalp, Arici, Odabas, Altiparmak et al., Mortality analysis of COVID-19 infection in chronic kidney disease, Frontiers in Pharmacology frontiersin
Qiao, Li, Zeng, Liu, Luo et al., SARS-CoV
Russo, Esposito, Taramasso, Magnasco, Saio et al., Kidney disease and all-cause mortality in patients with COVID-19 hospitalized in Genoa, Northern Italy, J. Nephrol,
doi:10.1007/s40620-020-00875-1Toussi, Neutel, Navarro, Preston, Shi et al., Pharmacokinetics of oral nirmatrelvir/ritonavir, a protease inhibitor for treatment of COVID-19, in subjects with renal impairment, Clin. Pharmacol. Ther,
doi:10.1002/cpt.2688Wang, Peng, Ye, Li, Li et al., Renin-angiotensin system inhibitor is associated with the reduced risk of all-cause mortality in COVID-19 among patients with/without hypertension, Front. Med,
doi:10.1007/s11684-021-0850-9Zhang, Zhou ; Flythe, Assimon, Tugman, Chang et al., Characteristics and outcomes of individuals with pre-existing kidney disease and COVID-19 admitted to intensive care units in the United States,
doi:10.1002/jmv.27491Zhu, Xiao, Meng, Tang, Li et al., Nanovesicles derived from bispecific CAR-T cells targeting the spike protein of SARS-CoV-2 for treating COVID-19, J. Nanobiotechnology,
doi:10.1186/s12951-021-01148-0DOI record:
{
"DOI": "10.3389/fphar.2023.1147980",
"ISSN": [
"1663-9812"
],
"URL": "http://dx.doi.org/10.3389/fphar.2023.1147980",
"abstract": "<jats:p><jats:bold>Background:</jats:bold> Nirmatrelvir/ritonavir has demonstrated effectiveness in high-risk patients with coronavirus disease 2019 (COVID-19). However, investigations on the efficacy and safety of nirmatrelvir/ritonavir in patients with kidney dysfunction are limited.</jats:p><jats:p><jats:bold>Methods:</jats:bold> Data were collected from the patients admitted to a COVID-19 referral center in Shanghai, China. Patients were at least 18 years of age and had a baseline estimated glomerular filtration rate (eGFR) of &lt;60 ml/min/1·73 m<jats:sup>2</jats:sup>. The primary endpoint was a composite of all-cause mortality, intensive care unit admission, or cardiovascular events. The secondary endpoint was viral shedding.</jats:p><jats:p><jats:bold>Results:</jats:bold> Among the 195 participants, 73 received nirmatrelvir/ritonavir. A lower risk of the primary endpoint was observed in nirmatrelvir/ritonavir recipients compared with non-recipients [adjusted HR 0.56 (95% CI: 0.32–0.96); <jats:italic>p =</jats:italic> 0.035]. Nirmatrelvir/ritonavir recipients experienced a shorter duration of viral shedding [adjusted HR 3·70 (95%CI: 2.60–5.28); <jats:italic>p</jats:italic> &lt; 0.001) and faster viral load clearance versus non-recipients. Among the nirmatrelvir/ritonavir users, earlier initiation of nirmatrelvir/ritonavir within 5 days since COVID-19 diagnosis was related with shorter viral shedding time (adjusted HR 7.84 [95% CI: 3.28–18.76]; <jats:italic>p</jats:italic> &lt; 0.001) compared to late initiation. No patients reported serious adverse events during treatment.</jats:p><jats:p><jats:bold>Conclusion:</jats:bold> Our findings support the early initiation of nirmatrelvir/ritonavir for high-risk patients with impaired kidney function. This could improve patient outcomes and shorten the viral shedding period.</jats:p>",
"alternative-id": [
"10.3389/fphar.2023.1147980"
],
"author": [
{
"affiliation": [],
"family": "Yan",
"given": "Jiayi",
"sequence": "first"
},
{
"affiliation": [],
"family": "Cai",
"given": "Hong",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Wang",
"given": "Jieying",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Zhu",
"given": "Mingli",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Li",
"given": "Ping",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Li",
"given": "Peiying",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Wu",
"given": "Bin",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Che",
"given": "Xiajing",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Gu",
"given": "Leyi",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Mou",
"given": "Shan",
"sequence": "additional"
}
],
"container-title": "Frontiers in Pharmacology",
"container-title-short": "Front. Pharmacol.",
"content-domain": {
"crossmark-restriction": true,
"domain": [
"frontiersin.org"
]
},
"created": {
"date-parts": [
[
2023,
3,
22
]
],
"date-time": "2023-03-22T04:57:51Z",
"timestamp": 1679461071000
},
"deposited": {
"date-parts": [
[
2023,
3,
22
]
],
"date-time": "2023-03-22T04:57:55Z",
"timestamp": 1679461075000
},
"funder": [
{
"DOI": "10.13039/501100001809",
"award": [
"81970574 82170685"
],
"doi-asserted-by": "publisher",
"name": "National Natural Science Foundation of China"
},
{
"DOI": "10.13039/100017950",
"award": [
"18ZXY001"
],
"doi-asserted-by": "publisher",
"name": "Shanghai Municipal Health Commission"
}
],
"indexed": {
"date-parts": [
[
2023,
3,
23
]
],
"date-time": "2023-03-23T04:58:22Z",
"timestamp": 1679547502953
},
"is-referenced-by-count": 0,
"issued": {
"date-parts": [
[
2023,
3,
22
]
]
},
"license": [
{
"URL": "https://creativecommons.org/licenses/by/4.0/",
"content-version": "vor",
"delay-in-days": 0,
"start": {
"date-parts": [
[
2023,
3,
22
]
],
"date-time": "2023-03-22T00:00:00Z",
"timestamp": 1679443200000
}
}
],
"link": [
{
"URL": "https://www.frontiersin.org/articles/10.3389/fphar.2023.1147980/full",
"content-type": "unspecified",
"content-version": "vor",
"intended-application": "similarity-checking"
}
],
"member": "1965",
"original-title": [],
"prefix": "10.3389",
"published": {
"date-parts": [
[
2023,
3,
22
]
]
},
"published-online": {
"date-parts": [
[
2023,
3,
22
]
]
},
"publisher": "Frontiers Media SA",
"reference": [
{
"DOI": "10.1056/NEJMoa2204919",
"article-title": "Nirmatrelvir use and severe covid-19 outcomes during the omicron surge",
"author": "Arbel",
"doi-asserted-by": "publisher",
"first-page": "790",
"journal-title": "N. Engl. J. Med.",
"key": "B1",
"volume": "387",
"year": "2022"
},
{
"DOI": "10.1111/joim.13239",
"article-title": "Increased vulnerability to COVID-19 in chronic kidney disease",
"author": "Carlson",
"doi-asserted-by": "publisher",
"first-page": "166",
"journal-title": "J. Intern Med.",
"key": "B2",
"volume": "290",
"year": "2021"
},
{
"DOI": "10.1016/j.ajpath.2022.01.007",
"article-title": "Signals of significantly increased vaccine breakthrough, decreased hospitalization rates, and less severe disease in patients with coronavirus disease 2019 caused by the omicron variant of severe acute respiratory syndrome coronavirus 2 in houston, Texas",
"author": "Christensen",
"doi-asserted-by": "publisher",
"first-page": "642",
"journal-title": "Am. J. Pathol.",
"key": "B3",
"volume": "192",
"year": "2022"
},
{
"DOI": "10.1016/j.cell.2021.12.046",
"article-title": "SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses",
"author": "Dejnirattisai",
"doi-asserted-by": "publisher",
"first-page": "467",
"journal-title": "Cell",
"key": "B4",
"volume": "185",
"year": "2022"
},
{
"key": "B5",
"volume-title": "Emergency use authorization for Paxlovid",
"year": "2022"
},
{
"DOI": "10.1038/s41392-022-00997-x",
"article-title": "SARS-CoV-2 omicron variant: Recent progress and future perspectives",
"author": "Fan",
"doi-asserted-by": "publisher",
"first-page": "141",
"journal-title": "Signal Transduct. Target Ther.",
"key": "B6",
"volume": "7",
"year": "2022"
},
{
"DOI": "10.1053/j.ajkd.2020.09.003",
"article-title": "Characteristics and outcomes of individuals with pre-existing kidney disease and COVID-19 admitted to intensive care units in the United States",
"author": "Flythe",
"doi-asserted-by": "publisher",
"first-page": "190",
"journal-title": "Am. J. Kidney Dis.",
"key": "B7",
"volume": "77",
"year": "2021"
},
{
"key": "B8",
"volume-title": "Coronavirus (COVID-19) update: FDA authorizes first oral antiviral for treatment of COVID-19",
"year": "2021"
},
{
"DOI": "10.1002/jmv.27491",
"article-title": "Omicron variant (B.1.1.529) of SARS-CoV-2, a global urgent public health alert",
"author": "Gao",
"doi-asserted-by": "publisher",
"first-page": "1255",
"journal-title": "J. Med. Virol.",
"key": "B9",
"volume": "94",
"year": "2022"
},
{
"DOI": "10.1161/JAHA.122.026143",
"article-title": "Renin-angiotensin system inhibitors in patients with COVID-19: A meta-analysis of randomized controlled trials led by the international society of hypertension",
"author": "Gnanenthiran",
"doi-asserted-by": "publisher",
"first-page": "e026143",
"journal-title": "J. Am. Heart Assoc.",
"key": "B10",
"volume": "11",
"year": "2022"
},
{
"DOI": "10.1038/d41586-021-03564-6",
"article-title": "Daily briefing: Omicron coronavirus variant puts scientists on alert",
"author": "Graham",
"doi-asserted-by": "publisher",
"journal-title": "Nature",
"key": "B11",
"year": "2021"
},
{
"DOI": "10.1056/NEJMoa2118542",
"article-title": "Oral nirmatrelvir for high-risk, nonhospitalized adults with covid-19",
"author": "Hammond",
"doi-asserted-by": "publisher",
"first-page": "1397",
"journal-title": "N. Engl. J. Med.",
"key": "B12",
"volume": "386",
"year": "2022"
},
{
"DOI": "10.1038/s41579-020-00459-7",
"article-title": "Characteristics of SARS-CoV-2 and COVID-19",
"author": "Hu",
"doi-asserted-by": "publisher",
"first-page": "141",
"journal-title": "Nat. Rev. Microbiol.",
"key": "B13",
"volume": "19",
"year": "2021"
},
{
"DOI": "10.1093/cid/ciaa1012",
"article-title": "Risk factors for intensive care unit admission and in-hospital mortality among hospitalized adults identified through the US coronavirus disease 2019 (COVID-19)-Associated hospitalization surveillance network (COVID-NET)",
"author": "Kim",
"doi-asserted-by": "publisher",
"first-page": "e206",
"journal-title": "Clin. Infect. Dis.",
"key": "B14",
"volume": "72",
"year": "2021"
},
{
"DOI": "10.7326/0003-4819-150-9-200905050-00006",
"article-title": "A new equation to estimate glomerular filtration rate",
"author": "Levey",
"doi-asserted-by": "publisher",
"first-page": "604",
"journal-title": "Ann. Intern Med.",
"key": "B15",
"volume": "150",
"year": "2009"
},
{
"DOI": "10.1128/aac.01229-22",
"article-title": "Pharmacokinetics of nirmatrelvir and ritonavir in COVID-19 patients with end-stage renal disease on intermittent hemodialysis",
"author": "Lingscheid",
"doi-asserted-by": "publisher",
"first-page": "e0122922",
"journal-title": "Antimicrob. Agents Chemother.",
"key": "B16",
"volume": "66",
"year": "2022"
},
{
"DOI": "10.1080/22221751.2022.2109517",
"article-title": "Geriatric risk and protective factors for serious COVID-19 outcomes among older adults in Shanghai Omicron wave",
"author": "Lu",
"doi-asserted-by": "publisher",
"first-page": "2045",
"journal-title": "Emerg. Microbes Infect.",
"key": "B17",
"volume": "11",
"year": "2022"
},
{
"DOI": "10.1136/bmj.n2713",
"article-title": "Covid-19: Pfizer's paxlovid is 89% effective in patients at risk of serious illness, company reports",
"author": "Mahase",
"doi-asserted-by": "publisher",
"first-page": "n2713",
"journal-title": "BMJ",
"key": "B18",
"volume": "375",
"year": "2021"
},
{
"DOI": "10.1186/s12951-021-01032-x",
"article-title": "The promising use of nano-molecular imprinted templates for improved SARS-CoV-2 detection, drug delivery and research",
"author": "Nahhas",
"doi-asserted-by": "publisher",
"first-page": "305",
"journal-title": "J. Nanobiotechnology",
"key": "B19",
"volume": "19",
"year": "2021"
},
{
"article-title": "Diagnosis and treatment plan for COVID-19 (trial version 9)",
"first-page": "73",
"journal-title": "Int. J. Epidemiol. Infect. Dis.",
"key": "B20",
"volume": "49",
"year": "2022"
},
{
"DOI": "10.1126/science.abl4784",
"article-title": "An oral SARS-CoV-2 M(pro) inhibitor clinical candidate for the treatment of COVID-19",
"author": "Owen",
"doi-asserted-by": "publisher",
"first-page": "1586",
"journal-title": "Science",
"key": "B21",
"volume": "374",
"year": "2021"
},
{
"DOI": "10.1093/ndt/gfaa271",
"article-title": "Mortality analysis of COVID-19 infection in chronic kidney disease, haemodialysis and renal transplant patients compared with patients without kidney disease: A nationwide analysis from Turkey",
"author": "Ozturk",
"doi-asserted-by": "publisher",
"first-page": "2083",
"journal-title": "Nephrol. Dial. Transpl.",
"key": "B22",
"volume": "35",
"year": "2020"
},
{
"DOI": "10.1126/science.abf1611",
"article-title": "SARS-CoV-2 M(pro) inhibitors with antiviral activity in a transgenic mouse model",
"author": "Qiao",
"doi-asserted-by": "publisher",
"first-page": "1374",
"journal-title": "Science",
"key": "B23",
"volume": "371",
"year": "2021"
},
{
"DOI": "10.1007/s40620-020-00875-1",
"article-title": "Kidney disease and all-cause mortality in patients with COVID-19 hospitalized in Genoa, Northern Italy",
"author": "Russo",
"doi-asserted-by": "publisher",
"first-page": "173",
"journal-title": "J. Nephrol.",
"key": "B24",
"volume": "34",
"year": "2021"
},
{
"DOI": "10.1002/cpt.2688",
"article-title": "Pharmacokinetics of oral nirmatrelvir/ritonavir, a protease inhibitor for treatment of COVID-19, in subjects with renal impairment",
"author": "Toussi",
"doi-asserted-by": "publisher",
"first-page": "892",
"journal-title": "Clin. Pharmacol. Ther.",
"key": "B25",
"volume": "112",
"year": "2022"
},
{
"DOI": "10.1007/s11684-021-0850-9",
"article-title": "Renin-angiotensin system inhibitor is associated with the reduced risk of all-cause mortality in COVID-19 among patients with/without hypertension",
"author": "Wang",
"doi-asserted-by": "publisher",
"first-page": "102",
"journal-title": "Front. Med.",
"key": "B26",
"volume": "16",
"year": "2022"
},
{
"DOI": "10.1016/S0140-6736(22)00838-8",
"article-title": "Shanghai's life-saving efforts against the current omicron wave of the COVID-19 pandemic",
"author": "Zhang",
"doi-asserted-by": "publisher",
"first-page": "2011",
"journal-title": "Lancet",
"key": "B27",
"volume": "399",
"year": "2022"
},
{
"DOI": "10.1016/S0140-6736(22)01530-6",
"article-title": "Protecting older people: A high priority during the COVID-19 pandemic",
"author": "Zhang",
"doi-asserted-by": "publisher",
"first-page": "729",
"journal-title": "Lancet",
"key": "B28",
"volume": "400",
"year": "2022"
},
{
"DOI": "10.1186/s12951-021-01148-0",
"article-title": "Nanovesicles derived from bispecific CAR-T cells targeting the spike protein of SARS-CoV-2 for treating COVID-19",
"author": "Zhu",
"doi-asserted-by": "publisher",
"first-page": "391",
"journal-title": "J. Nanobiotechnology",
"key": "B29",
"volume": "19",
"year": "2021"
}
],
"reference-count": 29,
"references-count": 29,
"relation": {},
"resource": {
"primary": {
"URL": "https://www.frontiersin.org/articles/10.3389/fphar.2023.1147980/full"
}
},
"score": 1,
"short-title": [],
"source": "Crossref",
"subject": [
"Pharmacology (medical)",
"Pharmacology"
],
"subtitle": [],
"title": "Nirmatrelvir/ritonavir for patients with SARS-CoV-2 infection and impaired kidney function during the Omicron surge",
"type": "journal-article",
"update-policy": "http://dx.doi.org/10.3389/crossmark-policy",
"volume": "14"
}
